Comparing new treatment combinations for relapsed or refractory multiple myeloma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of two treatment combinations involving talquetamab with either pomalidomide or teclistamab, compared to standard treatments that include elotuzumab or bortezomib along with pomalidomide and dexamethasone. Participants will be individuals with relapsed or refractory multiple myeloma who have previously received an anti-CD38 antibody and lenalidomide. The study is designed as a Phase 3 interventional trial to determine which combination provides better outcomes for patients. The effectiveness will be measured based on the response rates and progression-free survival of the participants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Documented multiple myeloma as defined by the criteria below: (a) multiple myeloma diagnosis according to the international myeloma working group (IMWG) diagnostic criteria (b) measurable disease at screening as assessed by central laboratory, defined by any of the following: (i) serum M-protein level greater than or equal to (\>=) 0.5 gram per deciliter (g/dL); or (ii) urine M-protein level \>= 200 milligram (mg) per 24 hours; or (iii) light chain multiple myeloma without measurable M-protein in the serum or the urine: serum immunoglobulin (Ig) free light chain (FLC) \>= 10 milligrams per deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio
* Relapsed or refractory disease as defined below: a) Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by IMWG criteria greater than (\>) 60 days after cessation of treatment. b) Refractory disease is defined as less than (\<) 25 percent (%) reduction in M-protein or confirmed PD by IMWG criteria during previous treatment or less than or equal to (\<=) 60 days after cessation of treatment
* Documented evidence of PD or failure to achieve a minimal response to the last line of therapy based on investigator's determination of response by IMWG criteria on or after their last regimen
* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment
* A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment

Exclusion Criteria:

* Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug or its excipients
* Stroke, transient ischemic attack, or seizure within 6 months prior to signing informed consent form (ICF)
* Major surgery or had significant traumatic injury within 2 weeks prior to the start of administration of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study or within 2 weeks after administration of the last dose of study treatment
* A maximum cumulative dose of corticosteroids of \>=140 mg of prednisone or equivalent within 14-day period before the first dose of study drug
* Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required

Where it's running

• UCSF Fresno
  Clovis, California, United States Recruiting
• UCLA
  Santa Monica, California, United States Recruiting
• Yale University School Of Medicine
  New Haven, Connecticut, United States Recruiting
• Medical Oncology Hematology Consultants, PA
  Newark, Delaware, United States Recruiting
• Memorial Healthcare System
  Hollywood, Florida, United States Recruiting
• Moffitt Cancer Center
  Tampa, Florida, United States Recruiting

+192 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Study Contact
• Email: Participate-In-This-Study1@its.jnj.com
• Phone: 844-434-4210

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using bispecific T-cell redirectors for first-line treatment in transplant-eligible multiple myeloma patients

  This study is testing if a new combination of treatments can help newly diagnosed multiple myeloma patients who are eligible for a stem cell transplant feel better and improve their outcomes.

  Recruiting Phase 2 North Estonia Medical Centre · Copenhagen and 6 other locations · NCT06505369

• Assessing the effectiveness of teclistamab for multiple myeloma

  This study is testing if teclistamab can help people with relapsed or hard-to-treat multiple myeloma who have already tried at least three other treatments.

  Recruiting at 16 sites Universitaire Ziekenhuizen KU Leuven · Bonheiden, Antwerpen and 16 other locations · NCT06477783

• Combination treatment for high-risk smoldering multiple myeloma

  This study is testing two different combination treatments to see which one helps people with high-risk smoldering multiple myeloma delay their disease from getting worse.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06100237

• Outpatient treatment for multiple myeloma using teclistamab or talquetamab

  This study is testing if two new treatments, teclistamab and talquetamab, can safely help adults with relapsed or hard-to-treat multiple myeloma when given as outpatient care.

  Recruiting at 16 sites Phase 2 SCRI Development Innovations, LLC · Tucson, Arizona and 16 other locations · NCT05972135

• Combination treatment for newly diagnosed multiple myeloma patients

  This study is testing a new combination treatment for people with newly diagnosed multiple myeloma to see if it can be a safer and more effective alternative to traditional high-dose therapy and stem cell transplants.

  Recruiting at 11 sites Phase 2 University of Heidelberg Medical Center · Berlin and 10 other locations · NCT05695508

• Combining teclistamab and talquetamab with daratumumab and lenalidomide for newly diagnosed multiple myeloma

  This study is testing two new treatment combinations for people with newly diagnosed multiple myeloma to see if they work better than the standard treatment.

  Recruiting at 66 sites Phase 3 Janssen Research & Development, LLC · Gilbert, Arizona and 269 other locations · NCT05552222

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.